Sorrento Therapeutics (SRNE) Competitors $0.0007 0.00 (0.00%) As of 03/28/2025 03:45 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsSustainabilityTrendsBuy This Stock SRNE vs. VCNX, PCSA, ERNA, BPTH, MBIO, WINT, GLMD, ADXS, VINC, and SYRSShould you be buying Sorrento Therapeutics stock or one of its competitors? The main competitors of Sorrento Therapeutics include Vaccinex (VCNX), Processa Pharmaceuticals (PCSA), Eterna Therapeutics (ERNA), Bio-Path (BPTH), Mustang Bio (MBIO), Windtree Therapeutics (WINT), Galmed Pharmaceuticals (GLMD), Ayala Pharmaceuticals (ADXS), Vincerx Pharma (VINC), and Syros Pharmaceuticals (SYRS). These companies are all part of the "pharmaceutical products" industry. Sorrento Therapeutics vs. Vaccinex Processa Pharmaceuticals Eterna Therapeutics Bio-Path Mustang Bio Windtree Therapeutics Galmed Pharmaceuticals Ayala Pharmaceuticals Vincerx Pharma Syros Pharmaceuticals Vaccinex (NASDAQ:VCNX) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation, community ranking and dividends. Which has more risk & volatility, VCNX or SRNE? Vaccinex has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500. Comparatively, Sorrento Therapeutics has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Do institutionals and insiders believe in VCNX or SRNE? 50.1% of Vaccinex shares are owned by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are owned by institutional investors. 51.5% of Vaccinex shares are owned by company insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community believe in VCNX or SRNE? Sorrento Therapeutics received 487 more outperform votes than Vaccinex when rated by MarketBeat users. Likewise, 67.85% of users gave Sorrento Therapeutics an outperform vote while only 60.00% of users gave Vaccinex an outperform vote. CompanyUnderperformOutperformVaccinexOutperform Votes12360.00% Underperform Votes8240.00% Sorrento TherapeuticsOutperform Votes61067.85% Underperform Votes28932.15% Does the media prefer VCNX or SRNE? In the previous week, Sorrento Therapeutics had 1 more articles in the media than Vaccinex. MarketBeat recorded 1 mentions for Sorrento Therapeutics and 0 mentions for Vaccinex. Vaccinex's average media sentiment score of 0.00 beat Sorrento Therapeutics' score of -0.40 indicating that Vaccinex is being referred to more favorably in the media. Company Overall Sentiment Vaccinex Neutral Sorrento Therapeutics Neutral Is VCNX or SRNE more profitable? Company Net Margins Return on Equity Return on Assets VaccinexN/A N/A -383.58% Sorrento Therapeutics N/A N/A N/A Which has stronger earnings & valuation, VCNX or SRNE? Vaccinex has higher earnings, but lower revenue than Sorrento Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaccinex$388K5.03-$20.25M-$48.27-0.02Sorrento Therapeutics$60.32M0.01-$572.84MN/AN/A SummarySorrento Therapeutics beats Vaccinex on 6 of the 11 factors compared between the two stocks. Remove Ads Get Sorrento Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRNE vs. The Competition Export to ExcelMetricSorrento TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$386,000.00$3.03B$5.63B$7.84BDividend YieldN/A1.55%5.33%4.01%P/E RatioN/A29.9323.5518.73Price / Sales0.01431.51388.1990.75Price / CashN/A168.6838.1734.64Price / BookN/A3.926.894.23Net Income-$572.84M-$71.95M$3.20B$247.47M7 Day PerformanceN/A-5.68%-3.06%-2.29%1 Month PerformanceN/A-12.09%1.51%-5.81%1 Year PerformanceN/A-27.90%9.37%-0.96% Sorrento Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRNESorrento TherapeuticsN/A$0.00flatN/A-91.3%$386,000.00$60.32M0.00800News CoverageVCNXVaccinexN/A$0.58+1.7%N/A-89.9%$1.51M$388,000.00-0.0140Upcoming EarningsGap DownPCSAProcessa Pharmaceuticals4.121 of 5 stars$0.44+2.0%$6.00+1,268.3%-83.6%$1.43MN/A-0.1320Short Interest ↓News CoveragePositive NewsGap UpERNAEterna Therapeutics1.0031 of 5 stars$0.26-1.7%N/A-92.7%$1.41M$582,000.00-0.0310News CoverageBPTHBio-Path1.6448 of 5 stars$0.16+5.4%$20.00+12,110.0%-96.2%$1.36MN/A0.0010Analyst ForecastNews CoverageMBIOMustang Bio2.8223 of 5 stars$1.41+0.7%$100.00+6,992.2%-97.4%$1.35MN/A-0.02100Short Interest ↓Gap UpWINTWindtree Therapeutics2.5222 of 5 stars$1.76+18.9%$350.00+19,786.4%-99.5%$1.32MN/A-0.1130Short Interest ↓Gap UpHigh Trading VolumeGLMDGalmed Pharmaceuticals1.2539 of 5 stars$2.03-10.2%N/A-61.7%$1.31MN/A-0.1220Upcoming EarningsAnalyst ForecastShort Interest ↑News CoverageGap DownADXSAyala PharmaceuticalsN/A$0.03flatN/A-93.0%$1.28M$3.24M0.0020Analyst ForecastGap UpVINCVincerx Pharma3.6727 of 5 stars$0.56-13.5%$40.00+7,037.8%-99.5%$1.26MN/A-0.0360Short Interest ↓Gap UpHigh Trading VolumeSYRSSyros Pharmaceuticals4.0124 of 5 stars$0.05-25.2%$3.33+7,146.4%-99.5%$1.23M$386,000.00-0.02120Analyst ForecastShort Interest ↑News CoverageGap Up Remove Ads Related Companies and Tools Related Companies Vaccinex Competitors Processa Pharmaceuticals Competitors Eterna Therapeutics Competitors Bio-Path Competitors Mustang Bio Competitors Windtree Therapeutics Competitors Galmed Pharmaceuticals Competitors Ayala Pharmaceuticals Competitors Vincerx Pharma Competitors Syros Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRNE) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersTrump to unlock 15-figure fortune for America (May 3rd) ?We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sorrento Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sorrento Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SRNE Stock Free SRNE Stock Alerts